B-Cell Malignant Neoplasm — Trials

B-Cell Malignant Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

7,465 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 2,083
Recruiting: 1,078
Ph III recruiting: 121
Growth YoY: +5.3%
Industry share: 26%
Top sponsor: National Cancer Institute (NCI)
Termination share: 35.1%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1,167)

clinicaltrialsPublishedShowing 51–100 of 363 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT07724457	Testing the Addition of a New Anti-Cancer Drug, Glofitamab to Usual Chemotherapy for Burkitt and Double Hit Lymphoma	not yet recruiting	Phase 2 / Phase 3	271	National Cancer Institute (NCI)NIH	0	Aug 19, 2026	clinicaltrials
NCT07774234	Sonrotoclax, Glofitamab, Gemcitabine, and Oxaliplatin for Relapsed or Refractory Large B-Cell Lymphoma	not yet recruiting	Phase 2	39	The First Affiliated Hospital of Soochow UniversityOTHER	1	Aug 19, 2026